Overview

Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)

Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
Primary Objectives: - To assess the safety of oral therapy with ZD6474 by evaluating the frequency, severity, and duration of treatment-emergent adverse events in patients with poor prognosis lung cancer. - To record the extent, frequency and duration of any tumor responses to this treatment regimen and assess whether ZD6474 augments the efficacy of radiation therapy in non-small cell lung cancer patients. - To determine the recommended phase II dose of ZD6474 for future clinical studies with radiation therapy. Secondary Objectives: - To determine the effects on metabolism and angiogenic factors by positron emission tomography (PET) scan/computed tomography (CT) scan , vascular endothelial growth factor (VEGF), and circulating endothelial cell levels in patients treated with ZD6474 and radiation therapy.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
AstraZeneca